{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 13,
  "pageCount": 28,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a dual-track timeline structure for different geographic regions.",
  "elementsJson": [
    "headline_text",
    "timeline_visual",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/13",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "framework",
      "text": "Timeline of clinical and regulatory milestones",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "beb999d7-d57b-40a8-94e0-3004d52e25a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "2016: EMA Scientific Advice; 2017: Pre-clinical & Manufacturing; 2018-2019: Phase IIB Dose Finding; 2020-2021: Phase III Pivotal; 2022: Marketing Authorisation",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22214bf2-907a-45f0-8be0-11d27fdcc8c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* EMA = European Medicines Agency; FDA = Food & Drug Administration; IND = Investigational New Drug; PMDA = Pharmaceuticals and Medical Devices Agency (Japan); TRD = Treatment-Resistant Depression",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07797fb2-d79c-4437-85b4-15c75c7a176b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "subtitle",
      "text": "Asia timeline: 2019 First mtg. PMDA; 2020+ To be determined",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deb71284-3c83-4ce6-a537-bbd6eded2744",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Psilocybin TRD Development Programme: Psilocybin therapy for treatment-resistant depression could be launched in 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33d35294-ad02-40cc-ba2f-87f7a5f507e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "e7b7b909-7d93-4a0b-8955-175152dc0ff5",
      "evidence": "Chronological progression of clinical and regulatory milestones",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "1b24f627-5397-46d5-a3ed-637425948073",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10 through 17 present psilocybin therapy as a solution, detailing its value proposition, development program, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}